secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2025-10-15T23:59:59+00:00
Accession:  0001437749-25-030968
Event type: m_and_a
Sentiment:  positive
Materiality: 0.95
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros sells global rights to zaltenibart to Novo Nordisk for up to $2.1B
-------------------------------------------------------------------------

- Upfront $240M cash plus near-term milestones total $340M; up to $2.1B including development & sales milestones plus tiered royalties.
- Novo Nordisk gains exclusive global rights to develop and commercialize MASP-3 inhibitor zaltenibart in all indications.
- Omeros will use part of upfront to repay $67.1M term loan; remaining funds support narsoplimab approval and preclinical pipeline.
- Transaction expected to close Q4 2025, subject to HSR clearance and customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000143774925030968/0001437749-25-030968-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000143774925030968/omer20251014_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-030968

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer